PRPH
ProPhase Labs, Inc.
Set alert
- YTD
- -98.33%
- 1 year
- -99.80%
- Open
- 0.008
- Prev close
- 0.008
- Mkt cap
- 116.94K
- Vol
- 71.74K
- Avg vol
- 327.92K
- EPS
- -0.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0075
- High
- 0.008
- Forward P/E
- 1.32
- Beta
- -0.10
- Short ratio
- 7.04
- Inst. own
- 7.63%
- Dividend
- 0.00
- Ex-div date
- May 23, 2022
- 50-d avg
- 1.34
- 200-d avg
- 3.39
- 1y target
- 18.50
Key statistics
- Market cap
- 15.13M
- Enterprise value
- 39.37M
- Trailing P/E
- 0.00
- Forward P/E
- 1.32
- PEG ratio
- 0.00
- Price / sales
- 0.84
- Price / book
- 0.23
- EPS (TTM)
- -1.53
- Beta
- -0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -146.39%
- Revenue (TTM)
- 17.97M
- Revenue growth
- -81.30%
- Free cash flow
- -3.72M
- Total cash
- 1.78M
- Total debt
- 26.82M
- Return on equity
- -50.92%
- Shares outstanding
- 23.87M
- Short % of float
- 0.97%
- 50-day average
- 1.34
- 200-day average
- 3.39
Analyst view
Consensus: none
- Target (low)
- 16.00
- Target (mean)
- 18.50
- Target (high)
- 21.00
Next earnings
Consensus EPS estimate -0.24.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.31 | -0.35 | -0.04 | -12.90% |
| Aug 14, 2024 | Jun 1, 2024 | -0.08 | -0.33 | -0.25 | -312.50% |
| May 9, 2024 | Mar 1, 2024 | -0.28 | -0.07 | +0.21 | +75.00% |
| Nov 9, 2023 | Sep 1, 2023 | -0.20 | -0.30 | -0.10 | -50.00% |
| Aug 10, 2023 | Jun 1, 2023 | -0.14 | -0.20 | -0.06 | -42.86% |
| May 11, 2023 | Mar 1, 2023 | -0.10 | 0.03 | +0.13 | +130.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 10, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 2, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 12, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 8, 2023 | HC Wainwright & Co. | reit | — | Buy |
About ProPhase Labs, Inc.
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- prophaselabs.com
News
- Comparing ProPhase Labs (NASDAQ:PRPH) and Aurora Cannabis (NASDAQ:ACB)
- Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)
- ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – What’s Next?
- ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – What’s Next?
- ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
- ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – Time to Sell?
- ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
- ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
- ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
- ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
Your note
Sign in to keep a note on PRPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KARKUS TED WILLIAM | Chief Executive Officer | Stock Gift | Apr 4, 2023 | 3,583,750 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.75% | 655,947 | 415.61K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.90% | 215,110 | 136.29K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.75% | 179,045 | 113.44K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.67% | 160,735 | 101.84K | Sep 29, 2024 |
| Perritt Capital Management, Inc. | 0.35% | 82,932 | 52.55K | Sep 29, 2024 |
| Blackrock Inc. | 0.29% | 69,381 | 43.96K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.90% | 454,645 | 288.06K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.76% | 181,391 | 114.93K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 87,697 | 55.56K | Oct 30, 2024 |
| Perritt Microcap Opportunities Fund | 0.17% | 40,000 | 25.34K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.16% | 37,848 | 23.98K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 22,224 | 14.08K | Oct 30, 2024 |